Furthermore, the molecular pathological mechanism of ITPR2 requires exploration in prospective studies, such as the use of phosphate binders, vitamin D preparations, and cinacalcet in basic research, as well as the design of more detailed clinical trials, including the evaluation of medications in CKD–MBD. This evidence concerns the gene ITPR2 and Marchiafava-Bignami disease.